Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Klein, D. J. Articles by Morrison, J. A. Search for Related Content PubMed Citation Articles by Klein, D. J. Articles by Morrison, J. A. Child/Adolescent Psychiatry Other Somatic Therapy Atypical Neuroleptics Related Article

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents

OBJECTIVE: Second-generation, or atypical, antipsychotics effectively treat psychiatric illness in children and adolescents. However, weight gain and abnormalities in insulin sensitivity, including diabetes, complicate this therapy. METHOD: A 16-week double-blind, placebo-controlled trial was conducted to evaluate the effectiveness of metformin in managing weight gain in 39 subjects, ages 10–17, whose weight had increased by more than 10% during less than 1 year of olanzapine, risperidone, or quetiapine therapy. Body weight, body mass index (kilograms per square meter of height), and waist circumference were measured regularly, as were fasting insulin and glucose levels. RESULTS: Weight was stabilized in subjects receiving metformin, while those receiving placebo continued to gain weight (0.31 kg/week). Because the study was conducted with growing children, metformin treatment resulted in reduction in z scores for both weight and body mass index. The homeostasis model assessment, a surrogate indicator of insulin sensitivity, decreased in treated subjects. Overt diabetes was diagnosed in two subjects before treatment (elevated baseline fasting glucose and insulin values) and in two placebo-treated subjects (one at week 12 and the other after study completion). One subject taking placebo developed impaired fasting glucose. Placebo treatment was associated with the need to perform oral glucose tolerance testing upon study completion, by which three additional subjects were identified with impaired glucose tolerance. No serious adverse events resulted from metformin treatment. CONCLUSIONS: Metformin therapy is safe and effective in abrogating weight gain, decreased insulin sensitivity, and abnormal glucose metabolism resulting from treatment of children and adolescents with atypicals.

Related Article:

In This Issue
Am J Psychiatry 2006 163: 68. [Full Text] [PDF]

This article has been cited by other articles:

				R.-R. Wu, J.-P. Zhao, X.-F. Guo, Y.-Q. He, M.-S. Fang, W.-B. Guo, J.-D. Chen, and L.-H. Li Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study Am J Psychiatry, March 1, 2008; 165(3): 352 - 358. [Abstract] [Full Text] [PDF]

				R. R. Prevost Pharmacy Review: Promoting Physical Activity in Youth: A Pharmacist's Reflections American Journal of Lifestyle Medicine, February 1, 2008; 2(1): 40 - 42. [Abstract] [PDF]

				R.-R. Wu, J.-P. Zhao, H. Jin, P. Shao, M.-S. Fang, X.-F. Guo, Y.-Q. He, Y.-J. Liu, J.-D. Chen, and L.-H. Li Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: A Randomized Controlled Trial JAMA, January 9, 2008; 299(2): 185 - 193. [Abstract] [Full Text] [PDF]

				S. Kumra, J. V. Oberstar, L. Sikich, R. L. Findling, J. M. McClellan, S. Vinogradov, and S. Charles Schulz Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia Schizophr Bull, January 1, 2008; 34(1): 60 - 71. [Abstract] [Full Text] [PDF]

				H. Y. Meltzer Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden PNAS, February 27, 2007; 104(9): 3019 - 3020. [Full Text] [PDF]

				Metformin May Influence Weight Gain from Atypicals Journal Watch Psychiatry, January 12, 2007; 2007(112): 2 - 2. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us